Logo

Response Biomedical Completes Share Consolidation

Sep 25, 2012 | staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical has completed a 20-for-one share consolidation, the Vancouver, British Columbia-based firm said yesterday after the close of the market.

The diagnostics firm said that it expects its post-consolidation common shares will begin trading on the Toronto Stock Exchange and the OTC Bulletin Board in the US on Sept. 26. It announced the share consolidation last month.

The shares were trading at $.08 on the OTC Bulletin Board, with no shares trading hands, early Tuesday afternoon.

Filed under

Diagnostics
Response Biomedical
Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.